Disclaimer - Kindly note that it takes approximately up to 6 months to implement the revised PI in commercial stocks imported into India after submission to the health authorities. All PIs notified to or approved by the CDSCO are published on this website for all the HCPs prescribing Roche drugs within 10 calendar days.

Safety Update Information for Healthcare Professionals (Oncology):

Direct Healthcare Professional Communication Alecensa® (Alectinib), Warning and Precaution and Specific Dose Modification Guidance for Management of Haemolytic AnaemiaDHPC package issued for Tecentriq regarding SCARs (Severe Cutaneous Adverse Reactions) an Identified Risk dated | 6th Nov 20205-Fluorouracil (i.v.), Capecitabine and Tegafur containing products: Pre-treatment testing to identify DPD deficient patients at increased risk of severe toxicity dated | 19th May 2020DHPC Tecentriq Atezolizumab Injection 1200mg/20ml Safety Update Identified risk -Immune-related myositis dated | 31st January 2019DHPC Xeloda Important Safety update of PI for Xeloda_DPD deficiency dated | 3rd October 2018DHPC Tecentriq Atezolizumab Injection 1200mg/20ml Important Identified risk immune related nephritis dated | 30th July, 2018DHPC Tecentriq Atezolizumab Injection 1200MG/20ML restriction to Tecentriq 1L Cisplatin-Ineligible mUC Indication dated | July 23, 2018

Safety Update Information for Healthcare Professionals. I understand the following:
1. The information contained in this website page is for the sole purpose of use and knowledge of Healthcare Professionals (HCPs) only.
2. If any Individual other than HCPs access the information contained in this website page and act thereon, then Roche will not be liable for any consequences in relation thereto.
3. Patients and their relatives should not access the information contained in this website page. They are advised to consult their treating physicians.
By clicking Agree, I hereby confirm that I am a Healthcare Professional and agree to the terms and conditions mentioned above.

This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin. This website is neither intended nor designed to record or report adverse event information. If you have a suspected side effect or problem to report regarding one of our products, visit us atOR please call the Roche India Safety Unit onor E-mail us at

ContactLocationslinkedinfacebooktwitterinstagramyoutubeAbout RochePersonalised HealthcareSolutionsRoche careersMediaPrivacy policyLegal statement